Stay updated with breaking news from Adicet Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced the appointm...
Adicet Bio, Inc. (NASDAQ:ACET – Get Free Report) has earned an average rating of “Moderate Buy” from the seven ratings firms that are presently covering the company, MarketBeat reports. Three analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price objective among […]
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a...
Adicet Bio (NASDAQ:ACET – Get Free Report) had its price objective lowered by research analysts at HC Wainwright from $26.00 to $10.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective points to a potential upside of 228.95% from […]
Adicet Bio (NASDAQ:ACET – Get Free Report) had its price objective reduced by analysts at HC Wainwright from $26.00 to $10.00 in a note issued to investors on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective indicates a potential upside of 228.95% from the stock’s current […]